The "Guardian of the Genome"-An Old Key to Unlock the ERCC1 Issue

Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly w...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 25; no. 8; pp. 2369 - 2371
Main Authors Friboulet, Luc, Soria, Jean-Charles, Olaussen, Ken André
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research 15.04.2019
Subjects
Cisplatin
DNA Adducts
DNA Repair
Life Sciences
Online AccessGet full text

Cover

More Information
Summary:Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy. .
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-18-4123